Kestrel doses first patient in Phase 1 trial of KST-6051 KRAS inhibitor
The company also announced a strategic warrant agreement with AbbVie for up to $1.45 billion, including an exclusive acquisition option.
Latest Kestrel Therapeutics News & Updates
See the latest news and media coverage for Kestrel. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing KRAS-targeted cancer therapies
kestreltherapeutics.com- Headquarters
- Watertown, United States
- Company type
- Private company
- Number of employees
- 20–50
Last updated
Latest news about Kestrel Therapeutics (Kestrel)
Company announcements
Kestrel announces FDA IND clearance for KST-6051
The Phase 1 trial FALCON will enroll patients with advanced KRAS-mutant solid tumors.
Media coverage
Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial
WATERTOWN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule inhibitors ...
Never miss news about Kestrel
Track Kestrel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
InnerPlant
AgVend
Futuremood
Melboss
Geo-Solutions
United Road
Packed Party
Purpose Legal
Allegrow
Sarah Flint
MycRX
Green River
System Surveyor
REED
Solu Therapeutics
FreightTrain
Wizard
Ascendant
Fence Supply Inc.
Milam & Greene
SAM
MRP
Greenbridge
Thirteen Lune
EmpowerLocal
Sensorium
WhistlePig
ALM First
Augment
Pegasus
ERG
Hunter Onsite
Tumbleweed Royalty